P380: A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis
ECCO '19 Copenhagen
2019
P381: Infliximab induction regimes in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis
ECCO '19 Copenhagen
2019
P382: Combination therapy with TNF-inhibitors and immunomodulators are associated with shorter duration to first serious infection: the DEVELOP experience
ECCO '19 Copenhagen
2019
P383: One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis
ECCO '19 Copenhagen
2019
P384: High incidence of hyperglycaemia in steroid treated hospitalised inflammatory bowel disease (IBD) patients and its risk factors identified by machine learning methods
ECCO '19 Copenhagen
2019
P385: TREM1, the first anti-TNF specific biomarker guiding therapeutic decision
ECCO '19 Copenhagen
2019
P386: Association of Infliximab trough levels and perianal disease activity in Crohn’s disease
ECCO '19 Copenhagen
2019
P387: Efficacy of combination therapy of fresh faecal microbiota transplantation and triple-antibiotic therapy for ulcerative colitis
ECCO '19 Copenhagen
2019
P388: Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme
ECCO '19 Copenhagen
2019
P389: Systematic review and meta-analysis of risk factors for recurrent primary sclerosing cholangitis
ECCO '19 Copenhagen
2019
P390: The impact of anti-TNF therapy in adjuvant setting on postoperative recurrence patterns over decades in complicated Crohn’s disease
ECCO '19 Copenhagen
2019
P391: Are cut-off ranges of Infliximab serum levels in Crohn’s disease always the same in clinical practice?
ECCO '19 Copenhagen
2019
P392: Body mass index has no effect on treatment response in Crohn's disease patients with moderate disease activity who receive adalimumab
ECCO '19 Copenhagen
2019
P393: Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on infliximab
ECCO '19 Copenhagen
2019
P394: Contribution of the CDEIS in the new therapeutic approach of Crohn's disease
ECCO '19 Copenhagen
2019
P395: Postoperative immunosuppressive therapies decrease the risk of second intestinal surgery in patients with Crohn’s disease: a retrospective cohort study
ECCO '19 Copenhagen
2019
P397: Autologous stem cell transplantation in refractory Crohn's disease: evaluation of a modified mobilisation regimen and analyses of the cost-effectiveness
ECCO '19 Copenhagen
2019